Busulfan and Melphalan Conditioning in Multiple Myeloma

NCT01923935

PHASE2INTERVENTIONAL

Chonnam National University Hospital

105 participants

Started 2013-01 · Completed 2015-12

Status: Unknown (as of 12-23-2025)

Conditions

Multiple Myeloma

Interventions

DRUG: BUSULFEX®DRUG: Alkeran®

Linked Papers (from SciSciNet-V2)

Total Papers31

Background

Result

Derived

Unknown

View on ClinicalTrials.gov

Total Citations Per Year

Brief Summary

The purpose of this study is to determine whether intravenous busulfan and melphalan as a conditioning regimen is effective in the treatment of multiple myeloma undergoing autologous stem cell transplantation.

Sort by:

Background Papers2

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers30

High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma

2003

1,759 citations

Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients

1993

1,173 citations

VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION

1987

898 citations

Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma

2006

749 citations

Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial

2002

562 citations

High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial

1998

553 citations

HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA

1983

515 citations

Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321

2006

505 citations

High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe

2005

402 citations

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

2006

374 citations

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

2005

343 citations

VAD‐based regimens as primary treatment for multiple myeloma

1990

320 citations

High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma

1987

270 citations

Multiple myeloma treated with high dose intravenous melphalan

1987

251 citations

INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMA

1989

198 citations

Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support

1992

177 citations

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM)

2009

170 citations

High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients

1993

138 citations

High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma.

1996

114 citations

Factors influencing collection of peripheral blood progenitor cells following high‐dose cyclophosphamide and granulocyte colony‐stimulating factor in patients with multiple myeloma

1997

112 citations

Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma

1999

101 citations

Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients

2007

89 citations

Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma

2000

78 citations

Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma

2002

50 citations

High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma.

1990

50 citations

Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma

1995

41 citations

High-dose busulfan in patients with myeloma.

1992

38 citations

Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system